Related Experiment Video
Updated: Nov 19, 2025
An Efficient Method for Adenovirus Production
Published on: June 10, 2021
Optimization of an E1A Gene Expression Cassette in an Oncolytic Adenovirus for Efficient Tumor Cell Killing Activity
Fuminori Sakurai1, Fumitaka Nishimae2, Kosuke Takayama2
1Laboratory of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan; sakurai@phs.osaka-u.ac.jp mizuguch@phs.osaka-u.ac.jp.
Background/Aim:
Oncolytic adenoviruses (OAds) have attracted much attention as novel anticancer therapeutics. The proper design of an expression cassette containing the E1A gene, which is indispensable for self-replication of the Ad genome, is crucial for efficient tumor cell-specific infection of an OAd. Various types of oncolytic adenoviruses (OAds) possessing different types of the E1A gene expression cassettes have been developed, but their oncolytic activities and safety profiles have not been systematically evaluated. Herein we examined the oncolytic activities and safety profiles of five types of OAds possessing different types of the E1A gene expression cassette in order to optimize the E1A gene expression cassette for development of an efficient and safe OAd.
Materials And Methods:
We prepared five types of OAds containing different types of E1 gene expression cassettes, and examined the oncolytic activities and safety profiles of the OAds.
Results:
Among the OAds examined, OAd-Δ24, which had a 24-bp deletion in the E1A gene, mediated the most efficient oncolytic activities against the human tumor cell lines, although OAd-Δ24 showed slightly higher cytotoxicity to normal human cells than the other OAds.
Conclusion:
These results provide important clues for the development of safe and efficient OAds.
Insights
Oncolytic adenoviruses (OAds) show promise as cancer therapies. A modified E1A gene in OAd-Δ24 demonstrated the highest tumor cell killing, though with slightly increased normal cell impact, guiding future OAd development.
Area of Science:
- Oncolytic virotherapy
- Gene therapy
- Cancer research
Background:
- Oncolytic adenoviruses (OAds) are emerging as potent anticancer agents.
- The E1A gene expression cassette is critical for OAd replication and tumor-specific targeting.
- Systematic evaluation of different E1A cassette designs is needed for optimal OAd development.
Purpose of the Study:
- To evaluate and compare the oncolytic activities and safety profiles of five distinct OAds with varying E1A gene expression cassettes.
- To identify an optimized E1A gene expression cassette for enhanced efficacy and safety in OAd-based cancer therapy.
Main Methods:
- Construction and preparation of five types of OAds, each featuring a unique E1A gene expression cassette.
- In vitro assessment of the oncolytic activities of these OAds against human tumor cell lines.
- Evaluation of the safety profiles, including cytotoxicity to normal human cells, for each OAd variant.
Main Results:
- OAd-Δ24, engineered with a 24-bp deletion in the E1A gene, exhibited the most potent oncolytic activity against tested human tumor cell lines.
- While highly effective, OAd-Δ24 displayed a marginally increased level of cytotoxicity towards normal human cells compared to other tested OAds.
- Variations in E1A gene expression cassettes significantly influenced the oncolytic efficacy and safety profiles of the OAds.
Conclusions:
- The findings highlight the critical role of E1A gene cassette design in determining OAd performance.
- OAd-Δ24 represents a promising candidate for oncolytic virotherapy, warranting further investigation for its therapeutic potential.
- This study provides valuable insights for the rational design of safer and more effective oncolytic adenoviruses for cancer treatment.
